Novartis and Amgen have expanded an existing collaboration with Arizona’s Banner Alzheimer’s Institute (BAI), and begun a major study investigating whether a BACE1 inhibitor drug can delay
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
